lansoprazole has been researched along with Acute Disease in 16 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 9.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 8.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| "Among the 15 patients with hemorrhagic acute gastritis who were randomly allocated to group A (eradication therapy) or group B (Lansoprazole, LPZ), 10 of them started to receive treatment within 1 day after the disease onset." | 5.09 | A short-term eradication therapy for Helicobacter pylori acute gastritis. ( Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T, 2000) |
| "To study in a double-blind controlled manner the effects of lansoprazole 15 mg or 30 mg daily compared with ranitidine 300 mg once daily and placebo in the relieving of symptoms and healing of acute duodenal ulceration." | 5.07 | Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Lanza, F; Scowcroft, C, 1994) |
| "The aim was to compare the clinical efficacy of lansoprazole with the efficacies of ranitidine and famotidine in order to rank this drug in the hierarchy of duodenal ulcer treatments." | 4.79 | Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. ( Agostini, H; Lemaire, M; Poynard, T, 1995) |
| "Dexlansoprazole DDR has the potential to outperform traditional PPIs based on the metabolism and novel pharmacokinetics." | 2.45 | Dexlansoprazole MR. ( Aslam, N; Wright, R, 2009) |
| " The results of studies comparing the clinical efficacy of different PPI dosage forms and routes of administration, safety considerations, and cost-effectiveness analyses are among the factors to consider when making formulary decisions for this class of drugs." | 2.43 | Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. ( Devlin, JW; Olsen, KM; Welage, LS, 2005) |
| "Patients with COPD in groups C and D in the stable phase were stratified into a group with neither gastroesophageal reflux nor lansoprazole therapy (group A) and a group subjected to oral lansoprazole therapy (group B1 ) and a group not subjected to oral lansoprazole therapy (group B2 )." | 1.43 | A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease. ( Ding, W; Liu, JM; Xiong, W; Zhang, QS; Zhao, W; Zhao, YF, 2016) |
| "Lansoprazole was more potent than omeprazole, famotidine and ranitidine in inhibiting gastric mucosal lesions and hemorrhagic shock- or stress-induced bleeding." | 1.29 | [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion]. ( Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Parton, JR | 1 |
| Ritchie, J | 1 |
| Xiong, W | 1 |
| Zhang, QS | 1 |
| Zhao, W | 1 |
| Ding, W | 1 |
| Liu, JM | 1 |
| Zhao, YF | 1 |
| Jose, J | 1 |
| Saravu, K | 1 |
| Khera, K | 1 |
| Jimmy, B | 1 |
| Shastry, BA | 1 |
| Aslam, N | 1 |
| Wright, R | 1 |
| Devlin, JW | 1 |
| Welage, LS | 1 |
| Olsen, KM | 1 |
| Güliter, S | 1 |
| Keleş, H | 1 |
| Ozkurt, ZN | 1 |
| Cengiz, DU | 1 |
| Kolukisa, E | 1 |
| Bender, E | 1 |
| Schmidt, SP | 1 |
| Frem, JC | 1 |
| Gold, BD | 1 |
| Shehata, BM | 1 |
| Cole, CR | 1 |
| Choné, L | 1 |
| Fléjou, JF | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 1 |
| Lanza, F | 1 |
| Goff, J | 1 |
| Scowcroft, C | 1 |
| Jennings, D | 1 |
| Greski-Rose, P | 1 |
| Poynard, T | 1 |
| Lemaire, M | 1 |
| Agostini, H | 1 |
| Mathias, SD | 1 |
| Castell, DO | 1 |
| Elkin, EP | 1 |
| Matosian, ML | 1 |
| Inatomi, N | 1 |
| Murakami, I | 1 |
| Asano, S | 1 |
| Inada, I | 1 |
| Satoh, H | 1 |
| King, VJ | 1 |
| Di Mario, F | 1 |
| Battaglia, F | 1 |
| Dal Bò, N | 1 |
| Leandro, G | 1 |
| Benedetti, E | 1 |
| Bottona, E | 1 |
| Caroli, A | 1 |
| Costan-Biedo, F | 1 |
| De Bastiani, R | 1 |
| Germanà, B | 1 |
| Andrea Grassi, S | 1 |
| Madia, D | 1 |
| Marcon, V | 1 |
| Marin, R | 1 |
| Monica, F | 1 |
| Olivieri, P | 1 |
| Orzes, N | 1 |
| Pilotto, A | 1 |
| Ronzani, G | 1 |
| Saggioro, A | 1 |
| Tafner, G | 1 |
| Nomura, H | 1 |
| Miyake, K | 1 |
| Kashiwagi, S | 1 |
| Sugiyama, T | 1 |
| Asaka, M | 1 |
3 reviews available for lansoprazole and Acute Disease
| Article | Year |
|---|---|
Dexlansoprazole MR.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Delayed-Action Preparatio | 2009 |
Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Capsules; Humans; Lansopr | 2005 |
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidin | 1995 |
4 trials available for lansoprazole and Acute Disease
| Article | Year |
|---|---|
Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Anti-Ulcer Agents; Double-Blind Metho | 1994 |
Health-related quality of life of patients with acute erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Analysis of Variance; Double-Blind Method; E | 1996 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; | 2000 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Ant | 2000 |
9 other studies available for lansoprazole and Acute Disease
| Article | Year |
|---|---|
Acute upper gastrointestinal bleed in the puerperium following weight reduction surgery.
Topics: Acute Disease; Adult; Bariatric Surgery; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; I | 2020 |
A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease.
Topics: Acute Disease; Administration, Oral; Aged; Cytokines; Female; Follow-Up Studies; Forced Expiratory V | 2016 |
Acute interstitial nephritis related to lansoprazole administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Anti-Ulcer Agents; Female; Humans; Lan | 2008 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; A | 2005 |
Extraintestinal heterotopic gastric tissue simulating acute appendicitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acute Disease; Aged; Appendicitis; Choristo | 2008 |
Reflux masquerader: acute Helicobacter pylori infection in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Bacterial Agents; Clarithr | 2008 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gast | 1996 |
PPIs vs H2RAs for erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Es | 1998 |